Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Biofil Chemicals & Pharmaceuticals Limited stock ₹20.50, price ₹30.51, that is 32.8% below the price, quality 50 out of 100. Rating: overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range ₹25.79 – ₹97.90 · fair‑value band ₹11.73 – ₹35.65 · the ₹30.51 price screens above the ₹20.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Biofil Chemicals & Pharmaceuticals in your weekly email
Every Wednesday you see whether Biofil Chemicals & Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Biofil Chemicals and Pharmaceuticals Limited engages in manufacturing and trading of pharmaceuticals in India. It operates through Pharmaceutical and Chemical divisions.
Show moreShow less
The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and packaging solutions.
It also provides job work service for manufacturing pharmaceutical drugs. Biofil Chemicals and Pharmaceuticals Limited was incorporated in 1985 and is based in Indore, India.
Stock analysis
Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) currently trades at ₹30.51, while our model-based Fair Value estimate is ₹20.50, 33% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹42.87 per share, and 4 of the 15 models we run sit above the ₹30.51 price.
Bear case: the Economic Profit group reads lowest at ₹8.31, and 11 of the 15 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹11.73 (bear) to ₹35.65 (bull), the price of ₹30.51 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Biofil Chemicals & Pharmaceuticals Limited reported revenue of ₹284M in FY2026 versus ₹224M in FY2022, a compound +6.1%/yr. Reported net income was ₹27.9M in FY2026, compounding +41.3%/yr from FY2022.
Key figures
Market cap ₹497M (≈ $5.3M) Micro · P/E ratio 179.5 · P/S ratio 1.43 · EPS (TTM) ₹0.1700 · Net margin 1.4% · Return on equity 13.8% · Return on assets (EBIT) 2.0% (5-year average) · Operating margin 1.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 34% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −33%, BIOFILCHEM screens richer than that median.
Fair Value models
Bear₹11.73Fair Value ₹20.50Bull₹35.65
Price ₹30.51 · Downside -32.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹0.1048 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ −20.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−20.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.18.2% vs 13.5%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 1%
Pace: the 5-year rate starts in 2021 (pandemic)
⚠ Rate on operating basis: 2026 sits 397% above its own trend.
Compare Biofil Chemicals & Pharmaceuticals Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside−32.8% · Below median
Profitability
Return on equity (12 months)13.8% · Top 25%
Return on assets6.5% · Above median
Net margin (12 months)1.4% · Below median
Operating margin (12 months)1.1% · Below median
Growth and dividend
Revenue growth (quarter YoY)34.0% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)179.5× · Priciest 25%
P/B2.30× · Pricier than median
P/S (12 months)1.43× · Cheaper than median
EV/EBITDA43.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 18
FUTURE (revenue growth)100· sector 25
PAST (return on equity)55· sector 25
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ₹20.50 versus a price of ₹30.51, about 33% lower (overvalued).
What is the fair value of BIOFILCHEM?
Our model-based fair value for Biofil Chemicals & Pharmaceuticals Limited is ₹20.50 (as of Nov 6, 2026), built from audited fundamentals. The current price: ₹30.51.
What is the quality score of BIOFILCHEM?
Biofil Chemicals & Pharmaceuticals Limited has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
Our model-based price target is the fair value of ₹20.50 (as of Nov 6, 2026) from 15 valuation models. Cautious scenario ₹11.73, optimistic scenario ₹35.65. It is a calculation from audited fundamentals, not an analyst target.
What is the Biofil Chemicals & Pharmaceuticals Limited stock forecast for 2026?
Our models put fair value at ₹20.50, about 33% lower versus a price of ₹30.51 (overvalued). Cautious scenario ₹11.73, optimistic scenario ₹35.65. The calculation is refreshed regularly with new filings.
What is the revenue of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
Biofil Chemicals & Pharmaceuticals Limited reported trailing-twelve-month revenue of about ₹346M (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biofil Chemicals & Pharmaceuticals Limited it is ₹20.50 per share (as of Nov 6, 2026), against a price of ₹30.51. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Biofil Chemicals & Pharmaceuticals Limited stock overvalued or undervalued in 2026?
As of Nov 6, 2026, BIOFILCHEM trades above its calculated fair value: price ₹30.51, fair value ₹20.50, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOFILCHEM?
No. The price is what the market pays today (₹30.51); the fair value is what the company's own numbers justify (₹20.50). For Biofil Chemicals & Pharmaceuticals Limited the two are ₹10.01 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biofil Chemicals & Pharmaceuticals Limited worth?
The market values Biofil Chemicals & Pharmaceuticals Limited at about ₹497M (market capitalisation, as of Nov 6, 2026). Per share that is ₹30.51; our models calculate a fair value of ₹20.50 per share.
What do the bullish and bearish scenarios say about BIOFILCHEM?
Our models span a range for Biofil Chemicals & Pharmaceuticals Limited: cautious scenario ₹11.73, base ₹20.50, optimistic ₹35.65 per share (as of Nov 6, 2026, price ₹30.51). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BIOFILCHEM?
Biofil Chemicals & Pharmaceuticals Limited trades at a price-to-earnings ratio of 179.5 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹20.50 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2018 to 2026), reported earnings: 86.3. Other multiples: P/B 2.3, P/S 1.4, EV/EBITDA 43.4.
How solid is the balance sheet of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
Balance-sheet figures for Biofil Chemicals & Pharmaceuticals Limited (as of Nov 6, 2026): return on equity 13.8%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is BIOFILCHEM from its 52-week high?
Biofil Chemicals & Pharmaceuticals Limited trades at ₹30.51, about 34% below its 52-week high of ₹46.34 and 18% above the low of ₹25.79 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹20.50 is for.
Which stocks are comparable to Biofil Chemicals & Pharmaceuticals Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biofil Chemicals & Pharmaceuticals Limited stock attractive at the current price?
The data as of Nov 6, 2026: price ₹30.51, calculated fair value ₹20.50 (−33%), Quality Score 50/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIOFILCHEM calculated?
We run Biofil Chemicals & Pharmaceuticals Limited through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹20.50 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Biofil Chemicals & Pharmaceuticals Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
The closing price on Nov 9, 2026 was ₹30.51. Our model-based fair value is ₹20.50, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biofil Chemicals & Pharmaceuticals Limited right now?
The model range is unusually wide (₹11.73 to ₹35.65). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) come from?
Earnings per share at Biofil Chemicals & Pharmaceuticals Limited grew +2.7 % a year from 2015 to 2026. Broken into its drivers: revenue per share +13.5 %, EBIT margin −22.3 %, tax rate +0.2 %, residual (interest, one-offs) +16.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Biofil Chemicals & Pharmaceuticals Limited
How large is the market capitalisation of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
The market capitalisation of Biofil Chemicals & Pharmaceuticals Limited is ₹497M (≈ $5.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
The price-to-sales ratio of Biofil Chemicals & Pharmaceuticals Limited is 1.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
Earnings per share at Biofil Chemicals & Pharmaceuticals Limited are ₹0.1700 (price ÷ EPS = P/E 179.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
The net margin of Biofil Chemicals & Pharmaceuticals Limited is 1.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
The return on equity (ROE) of Biofil Chemicals & Pharmaceuticals Limited is 13.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
On an EBIT basis the return on assets of Biofil Chemicals & Pharmaceuticals Limited is 2.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
The operating margin of Biofil Chemicals & Pharmaceuticals Limited is 1.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
Revenue at Biofil Chemicals & Pharmaceuticals Limited is growing +34.0% versus a year earlier (3y avg −1.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)?
Earnings per share at Biofil Chemicals & Pharmaceuticals Limited are growing −95.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) generate?
The free cash flow of Biofil Chemicals & Pharmaceuticals Limited is −₹8.2M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) hold?
Biofil Chemicals & Pharmaceuticals Limited holds more cash than debt, ₹3.1M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Biofil Chemicals & Pharmaceuticals Limited in the live analysis
One click puts Biofil Chemicals & Pharmaceuticals Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026